companion diagnostics
An Interview with Gerd Maass, VP for R&D at Roche Pharmaceuticals: Chapter 2 - Companion Diagnostics
May 03 by Pharmaceuticals & Biotechnology EditorAn Interview with Gerd Maass, VP for R&D at Roche Pharmaceuticals: Chapter 1 - DNA Sequencing
April 13 by Pharmaceuticals & Biotechnology EditorGerd Maass, Vice President for R&D at Roche Pharmaceuticals, shares his views on advances in companion diagnostics, DNA sequencing and biobanking. This segment on DNA sequencing addresses claims t...
How to Deliver Safer, More Efficacious Drugs to Market with Algorithmic Systems and In Silico Technologies
January 04 by Helen WinsorCorrado Priami, CEO and President of CoSBi (Centre for Computational and Systems Biology), joins Helen Winsor from Pharma IQ, to talk about how we can ensure the delivery of safer and more efficacio...
Delivering the Best Drugs to Market – With Companion Diagnostics
December 17 by Helen WinsorMads Ropke, Senior Scientist at LEO Pharma, joins Helen Winsor from Pharma IQ to discuss companion diagnostics and how we can ensure the delivery of safer and more efficacious drugs to market. First...
Personalised Medicine: Is Co-Development the Best Method for Companion Diagnostics?
December 10 by Pharma IQThe market potential for personalised medicines is growing, thanks to the opportunities they hold for both patients and drug developers. Research conducted by Tufts Center for the Study of D...
Is Co-development the Best Method for Companion Diagnostics?
April 24 by Paul de KoningPaul de Koning, Vice President, Head Global Clinical Pharmacology & Exploratory Development, Astellas Pharma Global Development, joins Pharma IQ to discuss targeted treatment and diagnostics....
Translating Biomarkers From the Laboratory to the Clinic
April 24 by Helen WinsorMads Røpke, Senior Scientist at LEO Pharma, joins Pharma IQ to discuss the global companion diagnostics market and how we can ensure the delivery of safer and more efficacious drugs to m...